Stories
Stories
September 13, 2024
We are proud to announce the publication of our latest peer-reviewed paper in ACS Omega. The new approach accelerates hit discovery, increases the chances of finding effective drug candidates.
May 8, 2023
This paper highlights the transformative potential of our deep neural network, AIMLinker, in the field of drug discovery for PROTAC design...
September 9, 2021
AnHorn Medicines, as one of the innovators in the field of Targeted Protein Degradation, we have commitment to identify novel E3 enzymes with a clear disease involvement to expand our target coverage.
April 29, 2021
AnHorn Medicines participated NBRP DEMO DAY to show our one-year progress in research and make connections with investors, global pharma R&D experts, talents, and partners in this field....
March 23, 2021
We are moving forward to Artificial Intelligence Drug Discovery. The AI-enabled AIMCADD® platform helps us to identify new targets and treatments easier, and better....
January 27, 2021
AnHorn Medicines’s achievements in 2020, including the smooth establishment for research, operation and finance that support us for considerable progress in 2021...
